Forendo Pharma
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 10.9m | <1m | 3.3m | 5.1m | 9.6m | 4.3m |
| % growth | 125 % | 121456 % | (98 %) | 1689 % | 53 % | 89 % | (55 %) |
| EBITDA | (3.9m) | 5.9m | (6.5m) | (4.6m) | (2.5m) | (3.7m) | (32.2m) |
| % EBITDA margin | (43067 %) | 54 % | (3541 %) | (139 %) | (50 %) | (38 %) | (741 %) |
| Profit | (6.3m) | 5.3m | (6.4m) | (6.4m) | (4.3m) | (15.2m) | (32.4m) |
| % profit margin | (70056 %) | 49 % | (3464 %) | (194 %) | (85 %) | (159 %) | (745 %) |
| R&D budget | <1m | 10.0m | <1m | 3.0m | 5.0m | - | - |
| R&D % of revenue | 100 % | 91 % | 108 % | 91 % | 99 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | €250k | Early VC | |
| N/A | €1.2m | Series A | |
€12.0m | Series A | ||
* | €3.0m | Debt | |
€4.0m | Early VC | ||
$5.6m | Early VC | ||
* | $75.0m Valuation: $75.0m 13.4x EV/LTM Revenues -26.9x EV/LTM EBITDA | Acquisition | |
| Total Funding | €22.6m | ||
Recent News about Forendo Pharma
EditForendo Pharma is a clinical-stage drug development company specializing in innovative therapeutic solutions for endometriosis. Operating in the biopharmaceutical sector, Forendo Pharma leverages its proprietary HSD17B platform to develop novel treatments aimed at addressing unmet medical needs in women's health. The company primarily serves patients suffering from endometriosis, a condition characterized by painful symptoms due to tissue similar to the lining inside the uterus growing outside it. Forendo Pharma's business model focuses on research and development (R&D) to create groundbreaking drugs, which are then brought to market through strategic partnerships and collaborations with major pharmaceutical companies. Revenue is generated through licensing agreements, milestone payments, and potential future sales of approved therapies. The company's investors include Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures, Vesalius Biocapital III Partners, and Sunstone Life Science Ventures.
Keywords: endometriosis, drug development, intracrinology, HSD17B platform, women's health, biopharmaceutical, R&D, licensing, partnerships, therapeutic solutions.